| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2337 | 1917 | 29 |
| Full Text Views | 21 | 3 | 1 |
| PDF Downloads | 22 | 4 | 1 |
Copolymer Adjuvants in Malaria Vaccine Development
Robert L. Hunter
Robert L. Hunter
Department of Pathology, Emory University, Vaxcel Corporation, Malaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Search for other papers by Robert L. Hunter in
Current site
Google Scholar
PubMed
Search for other papers by Robert L. Hunter in
Current site
Google Scholar
PubMed
Altaf A. Lal
Altaf A. Lal
Department of Pathology, Emory University, Vaxcel Corporation, Malaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Search for other papers by Altaf A. Lal in
Current site
Google Scholar
PubMed
Search for other papers by Altaf A. Lal in
Current site
Google Scholar
PubMed
Protection against virulent challenge with murine Plasmodium yoelii malaria was induced by immunization with whole killed blood-stage parasites in copolymer P1004 and detoxified lipopolysaccharide as adjuvant. Similar immunization with Freund's complete adjuvant and other water-in-oil emulsions failed to protect. Protection was associated with the production of antibody of the IgG2a isotype against epitopes measured by immunofluorescence. Several formulations that did not protect elicited high antibody titers measured by enzyme-linked immunosorbent assays or titers of other isotypes measured by indirect immunofluorescent assay. The results provide additional evidence that the adjuvants influenced both the isotype and specificity of antibody. The implications of these findings for vaccine development are discussed.
Author Notes
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2337 | 1917 | 29 |
| Full Text Views | 21 | 3 | 1 |
| PDF Downloads | 22 | 4 | 1 |